Natural plant products for control of cancer metastasis
Patent Number: US8865642
Executive Summary:
General Description:
It is an object of the invention to provide methods of treating cancer by inhibiting metastasis in a subject, comprising administering a composition comprising a therapeutically effective amount of an extract of Colocasia, such as Taro (Colocasia esculenta). The authors have identified a therapeutic agent derived from edible roots of the plant Colocasia esculenta, commonly known as Taro, and from Xanthosoma sagittifolium, commonly known as Malanga Blanca and Yautia. We have shown for the first time that a water soluble extract of the taro (and Malanga Blanca and Yautia) corm (TE) has potent anti-metastatic activity. Using two highly metastatic, estrogen receptor, progesterone receptor and Her-2/neu negative murine mammary tumor cells (line 66.1 and 410.4) transplanted to immune competent syngeneic mice, we have shown that TE can significantly inhibit the lung colonizing ability of both cell lines and spontaneous metastasis of 66.1 cells. We have also shown that addition of TE to 3 of 7 human or murine cancer cell lines profoundly affects cellular morphology and inhibited proliferation in 6 of 9 cancer cell lines in a dose-dependent manner. We also show that TE has anticyclooxygenase activity by inhibiting expression of COX-2, and therefore also has therapeutic potential, for example, in the treatment of inflammatory conditions or diseases.
Using two highly metastatic, estrogen receptor, progesterone receptor and Her-2/neu negative murine mammary tumor cells (line 66.1 and 410.4) transplanted to immune competent syngeneic mice, the authors have shown that TE can significantly inhibit the lung colonizing ability of both cell lines and spontaneous metastasis of 66.1 cells.
Strengths:
Weaknesses:
Patent Status:
Inventor Bio: Amy Fulton
http://www.medschool.umaryland.edu/profiles/Fulton-Amy/
Executive Summary:
- Invention Type: Therapeutic
- Patent Status: Active
- Patent Link: https://patents.google.com/patent/US8865642/
- Research Institute: University of Maryland - Baltimore
- Disease Focus: Metastatic disease, including breast and prostate cancer
- Basis of Invention: The invention provides compositions comprising soluble extracts or isolated polypeptides from the edible roots of the plant Colocasia, such as Colocasia esculenta, commonly known as Taro, and from Xanthosoma, such as Xanthosoma sagittifolium, commonly known as Malanga Blanca or Yautia. The compositions exhibit inhibitory effects on metastasis of cancer cells in particular breast and prostate cancer cells and have therapeutic pharmacological activity. Pharmaceutical compositions for the treatment of cancer by inhibiting metastasis, which comprises an effective amount of the described extract or isolated polypeptide thereof and optionally a pharmaceutical acceptable carrier are described
- How it works: A method of treating breast cancer by inhibiting metastasis in a subject in need thereof, comprising administering to the subject a composition comprising a therapeutically effective amount of an isolated polypeptide from Taro (Colocasia esculenta), or therapeutically effective amount of an extract of Xanthosoma, such as Malanga Blanca or Yautia (Xanthosoma sagittifolium)
- Lead Challenge Inventor: Amy Fulton
- Inventors: Amy Fulton, Namita Kundu
- Development Stage: Animal experiments
- Clinical Applications:
- Chemotherapeutic drug
General Description:
It is an object of the invention to provide methods of treating cancer by inhibiting metastasis in a subject, comprising administering a composition comprising a therapeutically effective amount of an extract of Colocasia, such as Taro (Colocasia esculenta). The authors have identified a therapeutic agent derived from edible roots of the plant Colocasia esculenta, commonly known as Taro, and from Xanthosoma sagittifolium, commonly known as Malanga Blanca and Yautia. We have shown for the first time that a water soluble extract of the taro (and Malanga Blanca and Yautia) corm (TE) has potent anti-metastatic activity. Using two highly metastatic, estrogen receptor, progesterone receptor and Her-2/neu negative murine mammary tumor cells (line 66.1 and 410.4) transplanted to immune competent syngeneic mice, we have shown that TE can significantly inhibit the lung colonizing ability of both cell lines and spontaneous metastasis of 66.1 cells. We have also shown that addition of TE to 3 of 7 human or murine cancer cell lines profoundly affects cellular morphology and inhibited proliferation in 6 of 9 cancer cell lines in a dose-dependent manner. We also show that TE has anticyclooxygenase activity by inhibiting expression of COX-2, and therefore also has therapeutic potential, for example, in the treatment of inflammatory conditions or diseases.
Using two highly metastatic, estrogen receptor, progesterone receptor and Her-2/neu negative murine mammary tumor cells (line 66.1 and 410.4) transplanted to immune competent syngeneic mice, the authors have shown that TE can significantly inhibit the lung colonizing ability of both cell lines and spontaneous metastasis of 66.1 cells.
Strengths:
- Targets metastatic disease, which is difficult to treat
Weaknesses:
- Metastasis is difficult to treat
Patent Status:
- Publication date 10-21-2014
- Filing date 12-17-2010
- Priority date 03-16-2010
Inventor Bio: Amy Fulton
http://www.medschool.umaryland.edu/profiles/Fulton-Amy/
